How GLP-1 Drugs Are Made: Why Manufacturing Methods Matter for Your Medicine

You’ve probably heard of Ozempic, Wegovy, and Mounjaro. But here’s something most patients never learn: the same drug, made by different manufacturers using different methods, can contain entirely different impurities—and nobody is required to tell you which version you’re getting. A 2020 study from Novo Nordisk found that GLP-1 drugs from five suppliers each had distinct impurity profiles, some of which may trigger immune responses. The manufacturing method matters more than most people realize.

What the evidence supports: GLP-1 drugs produced by different manufacturing methods (recombinant vs. chemical synthesis) contain measurably different impurity profiles. A peer-reviewed 2020 study confirmed that liraglutide from five different suppliers each had unique impurities compared to the originator product, and computational modeling suggested some of these could be immunogenic.
What’s overstated or unsupported: No clinical trial has directly compared patient outcomes between GLP-1 drugs made by different methods. The immunogenicity predictions are based on computer models, not observed adverse events. Millions of patients use these drugs safely regardless of production method.
⚕️ LyfeiQ Score: 7/10 — The science behind manufacturing differences is solid, but the clinical significance for individual patients remains unproven. Worth understanding, not worth panicking over.

What Does the Research Actually Show?

Two fundamentally different production approaches create the same active molecules—but not the same byproducts. GLP-1 receptor agonists like liraglutide and semaglutide can be manufactured either biologically (using genetically modified bacteria or yeast as production factories) or chemically (building the peptide from scratch, one amino acid at a time). Both methods produce the target molecule, but each generates its own characteristic set of unwanted substances.

In 2020, Arne Staby and colleagues at Novo Nordisk published a landmark comparison in Pharmaceutical Research. They analyzed liraglutide and semaglutide from multiple manufacturers using advanced analytical techniques. The findings were stark: every supplier’s product had a distinct impurity fingerprint. Recombinant production (the biological route) introduces host-cell proteins, bacterial endotoxins, DNA fragments, and occasionally misfolded versions of the target peptide. Chemical synthesis, by contrast, leaves behind truncated sequences, incomplete couplings, chemically misfolded chains, and residues from the reagents used during assembly.

The Staby team used computational modeling to predict whether these manufacturing-specific impurities might activate T cells—a key component of immune surveillance. Several impurities flagged as potentially immunogenic, meaning they could theoretically prompt the body to develop antibodies against the drug itself. When that happens (a phenomenon called anti-drug antibodies), the medication can become less effective over time or, rarely, cause allergic reactions.

A 2024 analysis by SK Pharmteco catalogued the specific impurity types associated with each route. The FDA’s own 2021 assessment of solid-phase peptide synthesis for liraglutide acknowledged that the manufacturing process is “highly complex with numerous reaction and purification steps” that have “considerable impact on identity, strength and purity.” Regulators explicitly noted “significant challenges in determining the safety profile” of these peptides—a candid admission from the agency responsible for approving them.

Physical stability also varied by manufacturer. Trace metals in the production environment accelerated formation of high-molecular-weight aggregates—essentially, clumps of peptide molecules stuck together. These aggregates are a known trigger for immune responses, and their prevalence differed across suppliers.

One important nuance: data from the SUSTAIN clinical trials showed lower immunogenicity for semaglutide compared to liraglutide. But this doesn’t resolve the broader concern. Different manufacturers using different production methods create different impurity profiles, and each carries its own theoretical risk.

What Should Patients Actually Know?

If your insurance switches your GLP-1 medication to a different manufacturer, you’re potentially receiving a product with a different impurity profile—even though the active ingredient is identical. Current regulations require the active ingredient to meet purity specifications (typically 95–98%), but the remaining 2–5%—the impurity fraction—can vary considerably in composition depending on how the drug was made. Regulators don’t require detailed characterization of these manufacturing-specific impurities, provided they fall within acceptable total limits.

Practically, this means: pay attention to how you respond to your specific medication, particularly if your prescription gets switched between manufacturers. Report any unusual reactions—injection site issues, reduced efficacy, or allergic symptoms—to your healthcare provider. Ask your pharmacist whether the manufacturer or production method changed if you notice differences. And understand that the active ingredient being identical does not mean the total product is identical.

That said, perspective matters. Millions of patients have used GLP-1 drugs safely and effectively across multiple manufacturers and production methods. The risk being described here is theoretical and based on computational predictions, not documented clinical harm. The Staby team themselves framed it as a call for better surveillance, not an alarm bell.

What Does Mainstream Medicine Say?

Regulatory agencies acknowledge the complexity but maintain that approved products meet safety standards. The FDA’s 2021 review of solid-phase peptide synthesis for liraglutide explicitly identified manufacturing complexity as a challenge for safety evaluation. The agency requires that each manufacturer demonstrate its product meets purity and potency specifications, but the framework treats products as equivalent if the active ingredient passes quality testing—regardless of what’s in the impurity fraction.

The European Medicines Agency (EMA) has taken a slightly more cautious position on follow-on biologics, generally requiring more clinical data for complex peptide products. Major academic medical centers, including those running the SUSTAIN trial program, have published immunogenicity data showing that GLP-1 agonists have favorable safety profiles overall, but the head-to-head comparisons across manufacturers that would settle the impurity question have not been conducted.

What Does the Integrative Perspective Add?

Compounding pharmacies have entered the GLP-1 space, raising additional manufacturing quality questions. During the FDA-declared shortage of semaglutide and tirzepatide, compounding pharmacies began producing their own versions. The broader integrative medicine community has raised concerns about quality control in compounding operations that lack the analytical infrastructure of large pharmaceutical manufacturers.

Proponents of personalized medicine suggest that compounding allows for dose customization and cost savings. Critics, including the FDA, have warned that compounded versions may not undergo the same rigorous impurity testing. In late 2024 and early 2025, the FDA took enforcement actions against several compounding pharmacies producing semaglutide, citing quality concerns. The debate highlights a central tension: access and affordability versus manufacturing rigor.

What’s the Public Conversation Getting Wrong?

Social media discussions about GLP-1 manufacturing tend to collapse into two extremes—neither of which matches the evidence. On TikTok and Instagram, popular wellness creators frequently warn about “fake Ozempic” and compounded semaglutide as though any non-Novo Nordisk product is dangerous. On the other side, telehealth influencers promoting compounded versions often dismiss manufacturing differences as irrelevant, framing cost as the only variable that matters.

The reality is more nuanced than either camp allows. Pharmacist and medication safety educator Dr. Rena Gozlan has noted on her YouTube channel that manufacturing method affects impurity profile but doesn’t automatically determine safety—what matters is testing, transparency, and regulatory oversight. Meanwhile, several physician creators on Substack and YouTube, including endocrinologist Dr. Brian Fertig, have called for better labeling so patients know which production method was used for their specific batch. The consensus among credible health communicators: the manufacturing conversation deserves nuance, not panic.

Where Does the Evidence End and the Marketing Begin?

The science on manufacturing differences is legitimate—the gap is in what those differences mean clinically. The Staby study is well-designed and peer-reviewed. The SK Pharmteco analysis provides useful categorization. The FDA’s acknowledgment of analytical challenges is credible. None of this is disputed.

But the leap from “different impurity profiles exist” to “you should only trust brand-name products” is where marketing overtakes evidence. Novo Nordisk—which funded the Staby study—has an obvious commercial interest in emphasizing the risks of competitor products. The research itself is sound, but its implications have been selectively amplified by parties with financial stakes in the outcome.

The honest position: we know that manufacturing methods produce different impurities. We have computational models suggesting some could be problematic. We do not have clinical evidence that patients are being harmed. And we do not have the head-to-head trials that would resolve the question. That’s an uncomfortable middle ground—exactly where the science actually stands.

What’s Coming Next?

Three priorities could close the knowledge gap. First, head-to-head clinical studies comparing GLP-1 drugs from different manufacturers—following patients for years, not months—would provide definitive data on whether impurity differences translate to outcome differences. Second, regulatory agencies could mandate impurity-specific safety data rather than relying on overall purity percentages; two drugs at 98% purity with entirely different impurity compositions represent different risk profiles. Third, as the patent landscape shifts and biosimilar GLP-1 products enter the market, standardized analytical methods for characterizing manufacturing-specific impurities should become a requirement, not an option. The technology exists—the mandate doesn’t.

What Is GLP-1 Manufacturing Quality’s LyfeiQ?

Credibility Rating: 7/10

Research Quality: 7/10 — Core study is peer-reviewed and methodologically sound, but limited to one research group with commercial ties
Regulatory Clarity: 5/10 — FDA acknowledges the complexity but hasn’t mandated impurity-specific testing across manufacturers
Clinical Relevance: 6/10 — Manufacturing differences are real and measurable, but clinical impact on patients remains undemonstrated
Risk-Benefit Ratio: Favorable — GLP-1 drugs have strong safety records overall; manufacturing concerns are theoretical, not observed
Medical Consensus: Manufacturing method affects impurity profiles, but no clinical evidence supports different safety outcomes between approved products

👉 Who should pay attention to this: Patients who have experienced reduced efficacy or injection site reactions after a manufacturer switch, clinicians overseeing long-term GLP-1 therapy, and anyone considering compounded GLP-1 products.

👉 Who can safely deprioritize this: Patients stable on a consistent GLP-1 prescription from a single manufacturer with no adverse effects. The theoretical risk doesn’t warrant changing a regimen that’s working.

⚕️ LyfeiQ Score: 7/10 — The manufacturing science is credible and the quality differences are real, but no clinical trial has shown they harm patients. Stay informed, monitor your own response to manufacturer switches, and ask questions—but don’t let this keep you from a medication that’s working for you.

References

Staby A, et al. Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharm Res. 2020;37(7):120. pubmed.ncbi.nlm.nih.gov
Biologically Expressed versus Synthetic GLP-1 Peptides: Quality, Impurities, and Potency Considerations. SK Pharmteco, 2024. skpharmteco.com
Quality Considerations in Solid Phase Peptide Synthesis: A Case Study with Liraglutide. U.S. Food and Drug Administration, 2021. fda.gov

Disclaimer: This content includes personal opinions and interpretations based on available sources and should not replace medical advice. This content includes interpretation of available research and should not replace medical advice. Although the data found in this blog and infographic has been produced and processed from sources believed to be reliable, no warranty expressed or implied can be made regarding the accuracy, completeness, legality or reliability of any such information. This disclaimer applies to any uses of the information whether isolated or aggregate uses thereof.